BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 11857074)

  • 21. Molecular alterations in primary prostate cancer after androgen ablation therapy.
    Best CJ; Gillespie JW; Yi Y; Chandramouli GV; Perlmutter MA; Gathright Y; Erickson HS; Georgevich L; Tangrea MA; Duray PH; González S; Velasco A; Linehan WM; Matusik RJ; Price DK; Figg WD; Emmert-Buck MR; Chuaqui RF
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6823-34. PubMed ID: 16203770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice.
    Tse E; Smith AJ; Hunt S; Lavenir I; Forster A; Warren AJ; Grutz G; Foroni L; Carlton MB; Colledge WH; Boehm T; Rabbitts TH
    Mol Cell Biol; 2004 Mar; 24(5):2063-73. PubMed ID: 14966285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for the recognition of ldb1 by the N-terminal LIM domains of LMO2 and LMO4.
    Deane JE; Mackay JP; Kwan AH; Sum EY; Visvader JE; Matthews JM
    EMBO J; 2003 May; 22(9):2224-33. PubMed ID: 12727888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis.
    Chung GT; Yamada Y; Pannell R; Forster A; Rabbitts TH
    Nucleic Acids Res; 2003 Apr; 31(8):e46. PubMed ID: 12682381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional control of fetal liver hematopoiesis: dominant negative effect of the overexpression of the LIM domain mutants of LMO2.
    Terano T; Zhong Y; Toyokuni S; Hiai H; Yamada Y
    Exp Hematol; 2005 Jun; 33(6):641-51. PubMed ID: 15911088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis.
    Amoh Y; Yang M; Li L; Reynoso J; Bouvet M; Moossa AR; Katsuoka K; Hoffman RM
    Cancer Res; 2005 Jun; 65(12):5352-7. PubMed ID: 15958583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
    Yamada Y; Pannell R; Forster A; Rabbitts TH
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):320-4. PubMed ID: 10618416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the key LMO2-binding determinants on Ldb1.
    Ryan DP; Sunde M; Kwan AH; Marianayagam NJ; Nancarrow AL; Vanden Hoven RN; Thompson LS; Baca M; Mackay JP; Visvader JE; Matthews JM
    J Mol Biol; 2006 May; 359(1):66-75. PubMed ID: 16616188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Lim-only protein LMO2 acts as a positive regulator of erythroid differentiation.
    Hansson A; Zetterblad J; van Duren C; Axelson H; Jönsson JI
    Biochem Biophys Res Commun; 2007 Dec; 364(3):675-81. PubMed ID: 17964543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
    Yamada Y; Pannell R; Forster A; Rabbitts TH
    Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vascular network of tumours--what is it not for?
    Sivridis E; Giatromanolaki A; Koukourakis MI
    J Pathol; 2003 Oct; 201(2):173-80. PubMed ID: 14517833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling approaches for angiogenesis.
    Taraboletti G; Giavazzi R
    Eur J Cancer; 2004 Apr; 40(6):881-9. PubMed ID: 15120043
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.